Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Discovery of breast cancer aggressiveness markers using topo-proteomics mapping

Project description

Identification of biomarkers for cancer aggressiveness

Tumours in breast cancer have been classified into several subtypes to determine patient prognosis and the appropriate treatment. Among the underlying causes of resistance to treatment and cancer relapse is the heterogeneity of tumours. In most cancers, tumours are composed of a heterogeneous mass of cells with distinct characteristics. The ERC-funded PROTEOMICAN project will study the tumour heterogeneity in breast cancer using the latest proteomic technologies. The genome-scale proteomic profiling of tumour regions with diverse histopathology will be followed by functional investigation to determine the tumorigenic potential of cells’ sub-populations. The identification of biomarkers for tumour aggressiveness in serum samples could be translated into new drugs that overcome the development of treatment resistance.

Objective

"In the proposed research we will explore the functional proteomic diversity of histologically-defined regions within human breast tumors, aiming to identify novel protein biomarkers of tumor aggressiveness. Once identified, these proteins will serve as potent diagnostic markers and therapeutic targets. Towards this aim we will perform genome-scale proteomic profiling on tumor regions displaying diverse histopathology. This will be followed by functional investigation of these cancer cell sub-populations to determine their tumorigenic potential, and search for microparticle-based proteomic biomarkers from serum samples towards identification of cancer aggressiveness in blood tests.
Analysis of the proteomic diversity holds a promise to reveal yet unidentified regulators of the tumorigenic phenotype as quantitative protein profiling is expected to most faithfully predict cellular phenotypes. This will be accomplished using the 'super-SILAC' technology, which I developed during my post-doctoral research. Using this technology, we identified over 12,000 proteins in formalin-fixed paraffin embedded breast cancer tumors. In the current project we will take one large step further, namely, microdissect and analyze selected regions in breast tumors based on local histopathological characteristics, such as the expression of known markers, cancer cell density, the vicinity to blood vessels and to the tumor invasive front. This ""topological map"" of the proteome will be followed by functional in vitro and in vivo studies, directly probing the aggressiveness of these cell populations, manifested by an accelerated proliferation and invasive/metastatic capacity. Finally, proteins associated with tumor aggressiveness will serve as blood-based biomarkers for predicting the tumorigenic phenotype using non-invasive tests. This work will set the basis for quantitative probing of tumor heterogeneity, which is crucial for accurate diagnosis and effective therapy.
"

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

ERC-STG - Starting Grant

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2014-STG

See all projects funded under this call

Host institution

TEL AVIV UNIVERSITY
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 1 699 260,75
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 1 699 261,00

Beneficiaries (1)

My booklet 0 0